Randomized controlled phase Ib study of ghrelin agonist, RM-131, in type 2 diabetic women with delayed gastric emptying: pharmacokinetics and pharmacodynamics

What Was Tested

This randomized controlled trial paper looks at Relamorelin in the context of delayed gastric emptying on glp-1 medicines.

Who Took Part

According to the abstract, 2 patients were involved.

PubMed tags the participants as women only.

GCSI daily diary (GCSI-DD) was completed during treatments.

PK was assessed in this cohort and healthy volunteers (HVs).

How the Study Was Run

The design is described as randomized, double-blind, placebo-controlled and crossover.

The patients were allocated by chance, so the Relamorelin group and the comparison group should start out alike.

Neither the patients nor the staff measuring them knew who was on Relamorelin, so expectations could not easily colour the readings.

The comparison arm used a placebo, so changes seen with Relamorelin could be set against what happens without it.

Each person switched between Relamorelin and the comparison at some point, usually with a gap in between.

Adverse events, plasma glucose, and hormonal levels were assessed.

What Was Measured

PubMed files the paper under topics including Diabetes Mellitus, Type 2, Gastric Emptying, Gastroparesis, Hypoglycemic Agents and Receptors, Ghrelin.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Relamorelin in 2 patients in people with delayed gastric emptying on glp-1 medicines.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Results are reported in around 9 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2013 (Diabetes care), a journal based in United States.

More context: the Relamorelin compound page, Delayed gastric emptying on GLP-1 medicines research.